The 2026 Norman R. Seay Lecture was held as part of a 2-part experience with guest lecturer Renã A. S. Robinson, PhD presenting on "Measures to Achieve Equity in Alzheimer’s Disease Research." This video is captured from the "Academic Lecture" event held at the Eric P. Newman Education Center on O

The Alzheimer’s risk gene APOE4 may actively damage brain blood vessels and sabotage the cellular systems that remove harmful proteins. Researchers were able to reverse some of these effects in experiments, revealing promising new targets for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

A new study from the University of Missouri offers hope for those who are at significantly higher risk of developing Alzheimer's disease later in life.

The 2026 Norman R. Seay Lecture was held as part of a 2-part experience with guest lecturer Renã A. S. Robinson, PhD presenting on "Measures to Achieve Equity in Alzheimer’s Disease Research." This video is captured from the "Community Conversation" event held at the Deaconess Foundation on Septem

WashU Medicine researchers found that dozens of blood proteins shifted during treatment with the anti-amyloid medication lecanemab, which could enable future blood tests monitoring a person's response to the drug.

Scientists have uncovered sweeping changes in how the human brain controls and organizes its genome beginning in midlife, offering new clues to why aging sharply increases the risk of Alzheimer’s and other neurodegenerative diseases. One of the biggest shifts occurred between about ages 50 and 75, when many of the brain’s original immune cells declined and were replaced by cells with more inflammatory characteristics. Researchers also found weakening of cells that help maintain the blood-brain barrier, along with widespread deterioration in the genome’s three-dimensional organization.

Exclusive: Alzheimer’s blood tests should not be used on their own and risk leading people to believe they are inevitably going to develop dementia

WashU Medicine researchers have found in mice that blocking immune cells in the body's lymph nodes significantly reduces neurodegeneration. The discovery reveals a previously unsuspected pathway that could potentially halt or slow the progression of Alzheimer’s and related diseases.

As the days grow shorter, don’t forget to spend some time outdoors. Exposure to outdoor light may be good for the health of the brain, according to a new repo

A new international study led by Concordia researchers finds that stronger brain waves during deep sleep may protect people with Alzheimer’s against cognitive decline associated with elevated levels of the neurotransmitter orexin. The three-year study suggests that sleep quality could help slow disease progression and may offer new avenues for monitoring and treatment. (concordia.ca)

The biomarker test, called PrecivityAD2, was developed from technology invented at WashU Medicine by Randall J. Bateman, MD, and David M. Holtzman, MD.

The U.S. Food and Drug Administration (FDA) has cleared an innovative blood test for marketing. The test's underlying technology was invented at Washington University School of Medicine in St. Louis for ...

The University of Rochester Medicine selected John Morris, MD, as the 2026 School of Medicine & Dentistry Distinguished Alumnus Award recipient! The recognition is presented to an alumnus who "exemplifies the standards and objectives of the School of Medicine & Dentistry through personal conduct, professional accomplishments, and community service."

Researchers mapped 830,000 brain immune cells, uncovering a protective microglia subtype that clears harmful material and slows Alzheimer’s disease progression.

Alzheimer's just gave up another one of its secrets.

Avoiding three risk factors for Alzheimer’s disease in midlife may allow you to live 13 years longer without dementia, according to a new analysis. The study

Digital newsstand featuring 7000+ of the world’s most popular newspapers & magazines. Enjoy unlimited reading on up to 5 devices with 7-day free trial.

WashU Medicine researchers and collaborators discovered three new chromosomal locations that may be connected to earlier disease onset or faster disease progression in dominantly inherited Alzheimer’s disease, pointing to new directions for Alzheimer’s research.

A protein that is a hallmark of Alzheimer’s disease may also ID a brain condition associated with head trauma in contact sports, early findings suggest.

Arts & Sciences researchers are working across disciplines to prevent, treat, and ultimately defeat Alzheimer’s disease.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

"SuperAgers" keep razor-sharp memories past 80, but a new study shows this is not just down to good genes.

Research led by WashU Medicine neurologist Jorge Llibre-Guerra, MD, provides the first direct evidence that some parts of Latin America are moving in the opposite direction of dropping dementia rates in the U.S. and other wealthy nations.

According to GlobalData, cases of MCI and Alzheimer’s are expected to increase to 26 million and 8.9 million cases, respectively, by 2033.

Researchers identified key ages when Alzheimer's-related brain changes speed up, while another study found blood tests still fall short of predicting cognitive decline.

A blood test that helps diagnose Alzheimer's might also forecast if healthy older adults will develop symptoms.

C-BRAIN, the consortium co-founded by WashU Medicine and directed by neurologist Randall J. Bateman, MD, brings together members from academia, major pharmaceutical companies and philanthropic organizations.

Already large clinical trials are testing if certain drugs could prevent or at least delay the disease - and if any of those pan out, doctors will need an easy way to tell who should try them.

Regularly sleeping long hours each night is associated with higher levels of an Alzheimer's-related protein in the blood, even after accounting for other health factors, a new study from UT Health San ...

A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

Founding members of the consortium include WashU Medicine, pharmaceutical companies, philanthropic groups and others.

Researchers found that tau is essential for turning new experiences into lasting memories by helping organize the brain's memory-storing cells. The mouse study also revealed how abnormal tau may contribute to Alzheimer's by disrupting both the formation of new memories and the recall of existing ones.

The Alzheimer's Association today announced the launch of the PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy), a first-of-its-kind global clinical trial designed to evaluate whether combining a proven multidomain lifestyle intervention with a metabolism-targeting drug, such as a GLP-1 agonist, can further reduce the risk of cognitive decline, mild cognitive impairment (MCI), and dementia in at-risk older adults.

"This highlights its potential as a disease-modifying therapy."

With new diagnostics and emerging therapies converging, Alzheimer’s disease (AD) care is shifting from late-stage symptom management to earlier

Obstructive sleep apnea syndrome (OSAS) is a prevalent sleep-related breathing disorder characterized by recurrent episodes of upper airway obstruction during sleep, resulting in intermittent reductions or complete cessation of airflow. These interruptions reduce oxygen saturation and disrupt normal sleep architecture, frequently resulting in daytime fatigue and adverse health outcomes. Recent research has provided increasing evidence that OSAS may be associated with neuroinflammation, defined as inflammation within the brain and nervous system. Such neuroinflammation may contribute to the development of conditions including depression, anxiety, Alzheimer’s disease, and Parkinson’s disease. This narrative review examines the association between OSAS and neuroinflammation and outlines the potential biological mechanisms involved. Intermittent hypoxemia and recurrent sleep fragmentation are thought to promote oxidative stress, neuroinflammation, and neuronal injury, ultimately contributing to impaired memory, executive function, emotional regulation, and overall neurological function. Over time, these processes can impair memory, executive function, emotional regulation, and overall neurological function. The review also highlights key risk factors and clinical manifestations and emphasizes the importance of early diagnosis and intervention for OSAS. Evidence from both experimental animal studies and human clinical studies is discussed to highlight current understanding while distinguishing established findings from emerging hypotheses. In summary, this review indicates that neuroinflammation may represent an important mechanistic pathway linking OSAS with depression, anxiety, cognitive impairment, and neurodegenerative disorders. However, much of the available evidence remains associative, and further longitudinal and biomarker-driven studies are required to clarify causal relationships and determine the long-term impact of interventions such as continuous positive airway pressure (CPAP) therapy. Improved understanding of these mechanisms may facilitate earlier diagnosis, risk stratification, and the development of targeted therapeutic strategies for individuals with OSAS.

A placebo-controlled trial put fish oil supplements to the test. Over two years, the supplements failed to slow cognitive decline in adults.

Researchers have identified a previously overlooked mechanism of brain cell death that appears to play a major role in Alzheimer's disease and frontotemporal dementia. The finding could lead to new treatments aimed at slowing neuron loss by interrupting the process before cells are destroyed.

Light exposure during the day may help lower the risk of developing cognitive issues, new research suggests. Here’s how to take advantage of this possible link.

Each year the Director of the Knight ADRC gives a lecture regarding the state of the Center. Upcoming State of the Knight ADRC Lectures are posted to our Events Calendar (https://knightadrc.wustl.edu/center-events/events-calendar/).

The 2026 Morby Prize from Cure Alzheimer’s Fund honors advances toward precision medicine and refined diagnosis of the disease.